RWE: Germany
Efficacy
PFS
ORR
53%
CR
32%
OS AT 12 MONTHS
53%
| Safety | |
|---|---|
| CRSGrade ≥3 | 13% |
| ICANSGrade ≥3 | 7% |
Limitations: Retrospective study and heterogeneity in patient selection across centers
- Reference: 1. Bethge WA et al. Blood. 2022;140(4):349-358.
Data collection
Nov 2018–Apr 2021
German Lymphoma Alliance (GLA) and the German Stem Cell Transplantation Registry (DRST)
Median follow-up
months
No. of patients infused with tisa-cel
| Median age (range) years | 61 (19–83) |
| Gender (male) | 64% |
| ECOG ≥2 | 16% |
| IPI (high/high-intermediate) | 57% |
| HG lymphoma(double or triple hit) | NR |
| DLBCL | 93% |
| Transformed lymphoma | 6% |
| Comorbidities | NR |
| LDH elevated | 55% >N |
| Prior therapies, median≥3 lines | NR74% |
| Refractory (at LD) | 66% |
| Prior SCTAutoAllo | 35%NR |
| Bridging therapy | 84% |
| Median vein to vein time | 55 days |
Limitations: Baseline characteristics differed between treatment groups with higher rates of BT and longer vein to vein time in the tisa-cel group
- Reference: 1. Bethge WA et al. Blood. 2022;140(4):349-358.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete